Ono Pharmaceutical (OTCMKTS:OPHLF) Stock Passes Above 50-Day Moving Average – Should You Sell?

Ono Pharmaceutical Co. (OTCMKTS:OPHLF) crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $14.38 and traded as high as $14.9740. Ono Pharmaceutical shares last traded at $14.71, with a volume of 345 shares traded.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded Ono Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, According to MarketBeat.com, Ono Pharmaceutical has an average rating of “Strong Buy”.

Ono Pharmaceutical Price Performance

The company has a quick ratio of 2.56, a current ratio of 3.02 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $6.91 billion, a PE ratio of 14.01 and a beta of 0.33. The firm’s 50 day simple moving average is $14.38 and its 200 day simple moving average is $14.81.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.